

TABLE 7

Summary of change from Baseline in IBS QOL (32 µg)									
Component/Scale Score									
	QOL Overall	Dysphoria	Interference with Activity	Body Image	Health Worry	Food Avoidance	Social Reaction	Sexual	Relationship
Baseline									
N	49	49	49	49	49	49	49	49	49
Mean	60.14	59.69	69.82	43.37	44.38	52.21	66.84	68.62	70.23
(Std)	22.05	24.79	23.385	24.387	24.672	32.175	28.562	31.367	23.385
Week 4									
N	36	36	36	36	36	36	36	36	36
Mean	11.25**	14.58**	7.04*	15.28**	16.9**	8.33*	9.9**	8.68**	7.64*
(Std)	16.277	20.39	17.753	18.264	17.534	23.988	16.46	18.131	18.831
Week 12									
N	33	33	33	33	33	33	33	33	33
Mean	13.08**	15.25**	9.42**	17.99**	19.44**	11.36**	10.8**	10.98**	9.09*
(Std)	13.527	15.285	18.052	15.21	21.616	23.46	14.173	18.424	20.87
End of Study									
N	44	44	44	44	44	44	44	44	44
Mean	12.58**	14.77**	8.2**	17.47**	17.61**	10.79**	11.08**	10.23**	10.79**
(Std)	12.621	14.429	16.726	15.344	22.317	21.906	14.32	16.894	20.139

TABLE 8

Summary of change from Baseline in IBS QOL (48 µg)									
Component/Scaled Score									
	QOL Overall	Dysphoria	Interference with Activity	Body Image	Health Worry	Food Avoidance	Social Reaction	Sexual	Relationship
Baseline									
N	45	45	45	45	45	45	45	45	45
Mean	59.85	56.81	68.25	45.69	44.07	50.37	66.81	71.94	75.18
(Std)	21.664	26.802	23.396	21.396	23.274	31.927	27.074	30.404	22.365
Week 4									
N	34	34	34	34	34	34	34	34	34
Mean	12.43**	17.28**	9.14**	13.24**	19.61**	12.01**	8.82**	8.46**	6.87**
(Std)	11.619	16.842	14.477	13.568	18.562	19.59	14.028	15.607	12.558
Week 12									
N	30	30	30	30	30	30	30	30	30
Mean	14.8**	20.83**	10.95**	17.08**	23.33**	11.3**9	14.17**	5	6.95**
(Std)	13.65	18.863	15.091	18.419	18.098	22.153	21.143	18.159	12.202
End of Study									
N	43	43	43	43	43	43	43	43	43
Mean	11.54**	16.28**	7.97**	14.24**	17.05**	8.33**	12.06**	3.49	6.01**
(Std)	13.002	18.62	14.387	17.43	19.067	20.002	18.72	17.535	12.244

*P < 0.05,

**P < 0.01 (paired T-Tests)

The description of the invention is merely exemplary in nature and, thus, variations that do not depart from the gist of the invention are intended to be within the scope of the invention. Such variations are not to be regarded as a departure from the spirit and scope of the invention.

All patents and publications cited in this specification are herein incorporated by reference

What is claimed is:

1. A method for the long term treatment of chronic constipation in a human subject, wherein the treatment comprises administering to the subject in need thereof an effective amount of a prostaglandin compound represented by Formula (I) and/or its tautomer: